Publications by authors named "Nelson R Rosado-Santander"
Article Synopsis
- SARS-CoV-2 may hinder a specific receptor in the body, and fenofibrate, which activates that receptor, was tested for its ability to reduce COVID-19 severity.
- A study involved 701 participants, giving some 145 mg of fenofibrate or a placebo for 10 days, measuring outcomes like death, hospitalization, and symptom severity.
- Results showed no significant difference between the fenofibrate and placebo groups in any key outcome, meaning fenofibrate didn't help in treating COVID-19.
Background: Biological considerations suggest that renin-angiotensin system inhibitors might influence the severity of COVID-19. We aimed to evaluate whether continuing versus discontinuing renin-angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) affects outcomes in patients admitted to hospital with COVID-19.
Methods: The REPLACE COVID trial was a prospective, randomised, open-label trial done at 20 large referral hospitals in seven countries worldwide.
Article Synopsis
- - The SARS-CoV-2 virus, causing COVID-19, is linked to serious health complications and increased mortality, particularly affecting multiple organs.
- - A global clinical trial started on March 31, 2020, to investigate the effects of continuing or stopping ACE inhibitors and ARBs in hospitalized COVID-19 patients.
- - The study focuses on several key health outcomes such as survival time, need for mechanical ventilation, and overall organ function, all while ensuring participant safety and ethical approval.